...
首页> 外文期刊>Molecular & cellular proteomics: MCP >Accurate Quantification of Cardiovascular Biomarkers in Serum Using Protein Standard Absolute Quantification (PSAQ?) and Selected Reaction Monitoring
【24h】

Accurate Quantification of Cardiovascular Biomarkers in Serum Using Protein Standard Absolute Quantification (PSAQ?) and Selected Reaction Monitoring

机译:使用蛋白质标准品绝对定量(PSAQ?)和选定的反应监测对血清中的心血管生物标志物进行准确定量

获取原文
获取原文并翻译 | 示例
           

摘要

Development of new biomarkers needs to be significantly accelerated to improve diagnostic, prognostic, and toxicity monitoring as well as therapeutic follow-up. Biomarker evaluation is the main bottleneck in this development process. Selected Reaction Monitoring (SRM) combined with stable isotope dilution has emerged as a promising option to speed this step, particularly because of its multiplexing capacities. However, analytical variabilities because of upstream sample handling or incomplete trypsin digestion still need to be resolved. In 2007, we developed the PSAQ? method (Protein Standard Absolute Quantification), which uses full-length isotope-labeled protein standards to quantify target proteins. In the present study we used clinically validated cardiovascular biomarkers (LDH-B, CKMB, myoglobin, and troponin I) to demonstrate that the combination of PSAQ and SRM (PSAQ-SRM) allows highly accurate biomarker quantification in serum samples. A multiplex PSAQ-SRM assay was used to quantify these biomarkers in clinical samples from myocardial infarction patients. Good correlation between PSAQ-SRM and ELISA assay results was found and demonstrated the consistency between these analytical approaches. Thus, PSAQ-SRM has the capacity to improve both accuracy and reproducibility in protein analysis. This will be a major contribution to efficient biomarker development strategies.
机译:新生物标志物的开发需要大大加快,以改善诊断,预后和毒性监测以及治疗性随访。生物标志物评估是该开发过程中的主要瓶颈。选定的反应监测(SRM)与稳定的同位素稀释相结合已成为加快此步骤的一个有前途的选择,特别是由于其多重能力。但是,由于上游样品处理或胰蛋白酶消化不完全引起的分析变异性仍需要解决。在2007年,我们开发了PSAQ?方法(蛋白质标准品绝对定量),使用全长同位素标记的蛋白质标准品定量目标蛋白质。在本研究中,我们使用经过临床验证的心血管生物标志物(LDH-B,CKMB,肌红蛋白和肌钙蛋白I)来证明PSAQ和SRM(PSAQ-SRM)的组合可以在血清样品中进行高度准确的生物标志物定量。多重PSAQ-SRM分析用于量化心肌梗死患者临床样品中的这些生物标志物。发现PSAQ-SRM与ELISA测定结果之间具有良好的相关性,并证明了这些分析方法之间的一致性。因此,PSAQ-SRM有能力提高蛋白质分析的准确性和可重复性。这将对有效的生物标记物开发策略做出重大贡献。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号